Assessing Regenxbio: Insights From 4 Financial Analysts

Loading...
Loading...

In the latest quarter, 4 analysts provided ratings for Regenxbio RGNX, showcasing a mix of bullish and bearish perspectives.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 0 0 0 0
Last 30D 1 0 0 0 0
1M Ago 1 0 0 0 0
2M Ago 1 0 0 0 0
3M Ago 1 0 0 0 0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $38.0, with a high estimate of $40.00 and a low estimate of $36.00. Observing a 5.56% increase, the current average has risen from the previous average price target of $36.00.

Deciphering Analyst Ratings: An In-Depth Analysis

The standing of Regenxbio among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Paul Choi Goldman Sachs Announces Buy $38.00 -
Yi Chen HC Wainwright & Co. Raises Buy $38.00 $36.00
Annabel Samimy Stifel Maintains Buy $40.00 -
Yi Chen HC Wainwright & Co. Announces Buy $36.00 -

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regenxbio. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regenxbio compared to the broader market.
  • Price Targets: Analysts predict movements in price targets, offering estimates for Regenxbio's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Regenxbio's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Regenxbio analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into Regenxbio's Background

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio: Financial Performance Dissected

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Regenxbio's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -18.37%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Regenxbio's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -405.39% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Regenxbio's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -18.03% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Regenxbio's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -10.53% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.22, caution is advised due to increased financial risk.

How Are Analyst Ratings Determined?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...